Numab Therapeutics AG’s Post

View organization page for Numab Therapeutics AG, graphic

5,637 followers

We are excited to announce today that Numab and ONO PHARMACEUTICAL CO., LTD. entered a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers, identified through Numab’s proprietary discovery and engineering technology platform.   This collaboration with a leading pharma company further validates Numab’s unique plug-and-play antibody technology platform and demonstrates its ability to continue to generate exciting candidates for the treatment of cancer and inflammatory diseases.   To learn more, please read our press release:  https://lnkd.in/dfsii_J3

240209_PRR_Numab-Therapeutics-Announces-Co-Development-Agreemtent-ND049_PRESS-RELEASE.pdf

240209_PRR_Numab-Therapeutics-Announces-Co-Development-Agreemtent-ND049_PRESS-RELEASE.pdf

numab.com

Klingt spannend, vielversprechend und sinnstiftend gratuliere herzlich dem Numab-Team

Like
Reply
Michael Karl Bauer

Partner at Novo Holdings Venture Investments

8mo

Congrats and well done Numab team!

Like
Reply
Scott Peterson

Corporate and Business Development

8mo

Yay! Congrats to the Numab team!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics